Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethyl eicosapentaenoic acid - Mochida Pharmaceutical

Drug Profile

Ethyl eicosapentaenoic acid - Mochida Pharmaceutical

Alternative Names: eicosapentaenoic acid ethyl ester; EPA-E; Epadel; Epadel-T; ethyl icosapentaenoate; ethyl icosapentate; MND-21; MND-2119

Latest Information Update: 11 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mochida Pharmaceutical
  • Class Antidepressants; Antihyperlipidaemics; Antineoplastics; Antiplatelets; Eicosanoids; Esters; Omega 3 fatty acids; Reactive oxygen species; Small molecules
  • Mechanism of Action Caspase inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Hyperlipidaemia
  • Phase III Hypertriglyceridaemia
  • Discontinued Alzheimer's disease; Chronic heart failure; Non-alcoholic steatohepatitis

Most Recent Events

  • 05 Nov 2018 Mochida Pharmaceutical and Sumitomo Dainippon plan a phase I trial in Hypertriglyceridaemia in China (Mochida Pharmaceutical pipeline, December 2018)
  • 27 Oct 2018 Phase-III clinical trials in Hypertriglyceridaemia (In adults, In the elderly) in Japan (PO) (NCT03693131)
  • 02 Oct 2018 Mochida Pharmaceutical Company plans a phase III trial for Hypertriglyceridemia in Japan (NCT03693131)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top